Thrombosis and haemostasis最新文献_第2页

Antiplatelet Therapy in Percutaneous Coronary Intervention Patients with Concurrent High Ischemic and Bleeding Risk. PCI并发高缺血和出血风险患者的抗血小板治疗。

IF 5 2区医学

Thrombosis and haemostasis Pub Date : 2025-08-01 Epub Date: 2025-02-24 DOI: 10.1055/a-2544-6263

Maria Sara Mauro, Davide Capodanno

引用次数: 0

Time trends in cause-specific mortality in patients with pulmonary embolism aged 50 years and older. 50岁及以上肺栓塞患者病因特异性死亡率的时间趋势

IF 4.3 2区医学

Thrombosis and haemostasis Pub Date : 2025-07-29 DOI: 10.1055/a-2668-5296

Katarina Glise Sandblad, Kristina Svennerholm, Jacob Philipson, Maria Roupe, Aldina Pivodic, Andrea Dahl Sturedahl, Carl Johan Svensson, Sam Schulman, Mazdak Tavoly

{"title":"Time trends in cause-specific mortality in patients with pulmonary embolism aged 50 years and older.","authors":"Katarina Glise Sandblad, Kristina Svennerholm, Jacob Philipson, Maria Roupe, Aldina Pivodic, Andrea Dahl Sturedahl, Carl Johan Svensson, Sam Schulman, Mazdak Tavoly","doi":"10.1055/a-2668-5296","DOIUrl":"https://doi.org/10.1055/a-2668-5296","url":null,"abstract":"Background Patients with pulmonary embolism (PE) have high mortality rates, particularly patients 50 years of age. However, data on trends in cause-specific mortality in this population are limited. Aims To study time trends in cause-specific mortality among PE patients aged 50 years from 2006 to 2023, analyzed across four periods: 2006-2012, 2013-2019, 2020-2021, and 2022-2023. The secondary aim was to study all-cause mortality trends. Methods This nationwide Swedish register study included patients with a first-time PE. We assessed 30-day and 31-365-day cause-specific mortality using data from the National Cause of Death Register and employed age- and sex-adjusted Poisson regression to determine the relative risk (RR) for annual mortality trends. Results The study comprised 115,476 patients, with cancer as the leading cause of 30-day mortality, stable at 4.7% in 2006-2012 to 5% in 2022-2023; RR 1.00 (95% confidence interval, CI: 0.99-1.01). Mortality from fatal venous thromboembolism (VTE) decreased from 2.6% to 1.3%; 0.94 (0.93-0.95), and cardiovascular disease from 2.3% to 1.0%; 0.94 (0.93-0.94). The 31 to 365-day mortality from cancer was stable, 12.0% in 2006-2012 and 11.9% in 2022; RR 1.00 (95% CI: 0.99-1.00), while mortality due to cardiovascular disease decreased from 4.1% to 2.3%; 0.96 (0.95-0.96), and fatal VTE; 0.8% to 0.3%; 0.95 (0.93-0.96). Conclusions Cancer was the leading cause of death for both 30-day and 31-365-day mortality in PE patients aged ≥50 years, remaining stable over time, while fatal VTE and cardiovascular disease mortality declined. Fatal VTE comprised a minor percentage of overall mortality in recent years.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144745131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Venous Thromboembolism Outcomes Among Cancer and Non-cancer Patients Managed with Patient-centric Guideline-driven Protocol. 采用以患者为中心的指南驱动方案管理的癌症和非癌症患者的静脉血栓栓塞结局

IF 4.3 2区医学

Thrombosis and haemostasis Pub Date : 2025-07-25 DOI: 10.1055/a-2653-6161

Claire E Cassianni, Robert D McBane, Danielle T Vlazny, David O Hodge, Ana I Casanegra, Damon E Houghton, Waldemar E Wysokinski

{"title":"Venous Thromboembolism Outcomes Among Cancer and Non-cancer Patients Managed with Patient-centric Guideline-driven Protocol.","authors":"Claire E Cassianni, Robert D McBane, Danielle T Vlazny, David O Hodge, Ana I Casanegra, Damon E Houghton, Waldemar E Wysokinski","doi":"10.1055/a-2653-6161","DOIUrl":"https://doi.org/10.1055/a-2653-6161","url":null,"abstract":"Patients with cancer and venous thromboembolism (VTE) have higher complication rates of anticoagulation. However, studies supporting this data are relatively old reflecting the era of vitamin K inhibitors.To assess VTE recurrence, major bleeding, and clinically relevant non-major bleeding (CRNMB) in patients (March 1, 2013 to April 30, 2023) with cancer-associated VTE and patients without cancer, the prospective Mayo Clinic Thrombophilia Clinic Registry was analyzed.Over the study period, 4,711 patients with acute VTE were enrolled including 2,064 patients with cancer (mean age 62.5 ± 12.4, 46% female) and 2,647 patients without cancer (mean age 59.4 ± 16.0, 45% female). The most common cancers were gastrointestinal (n = 423, 21%), pancreatic (n = 287, 14%), and genitourinary (n = 198, 10%). Direct oral anticoagulants were used in 1,339 (65%) cancer and in 1,952 (74%) non-cancer patients. Among cancer patients, 12-month Kaplan-Meier probability of VTE recurrence was 2.4-fold greater (7.1% vs. 2.9%, p < 0.001) compared with the non-cancer group, including higher recurrent leg deep vein thrombosis (3.0% vs. 1.4%; p = 0.002) and pulmonary embolism (3.5% vs. 1.0%, p < 0.001). Patients with cancer also had 2.1-fold greater risk of major bleeding (6.3% vs. 3.0%; p < 0.001) including bleeding from the gastrointestinal tract (3.0 vs. 1.4, p = 0.01) compared with patients without cancer. Clinically relevant non-major bleeding events were similar between the groups.In this large prospective registry of VTE management, patients with cancer had significantly higher rates of VTE recurrence and major bleeding compared with patients without cancer, yet the rate of complications are substantially smaller relative to historic values of a prior vitamin K antagonist era.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

NF-κB-mediated upregulation of tissue factor contributes to the procoagulant phenotype of smooth muscle cells from abdominal aorta aneurysm in human. NF-κ b介导的组织因子上调参与人腹主动脉瘤平滑肌细胞的促凝表型。

IF 4.3 2区医学

Thrombosis and haemostasis Pub Date : 2025-07-25 DOI: 10.1055/a-2665-2510

Veronique Regnault, Melusine Didelot, Véronique Ollivier, Cécile Lakomy, Jeremy Lagrange, Huguette Louis, Cecile Denis, Serguei Malikov, Patrick Lacolley, Jean-Baptiste Michel

{"title":"NF-κB-mediated upregulation of tissue factor contributes to the procoagulant phenotype of smooth muscle cells from abdominal aorta aneurysm in human.","authors":"Veronique Regnault, Melusine Didelot, Véronique Ollivier, Cécile Lakomy, Jeremy Lagrange, Huguette Louis, Cecile Denis, Serguei Malikov, Patrick Lacolley, Jean-Baptiste Michel","doi":"10.1055/a-2665-2510","DOIUrl":"https://doi.org/10.1055/a-2665-2510","url":null,"abstract":"Background: Aneurysms of the thoracic (TAA) and abdominal aorta (AAA) have different pathophysiological mechanisms, AAA has an intraluminal thrombus while TAA has not. This suggests a prothrombotic phenotype in AAA, probably at the level of vascular smooth muscle cells (SMCs) known to express tissue factor (TF).Objectives: To explore the TF-dependent thrombin generation in SMCs in AAA compared to TAA and healthy aorta (HA) and the underlying mechanisms contributing to a procoagulant phenotype.Methods: Human HA, AAA or TAA tissues and corresponding SMC primary cultures were used to analyze SMC-supported thrombin generation and TF expression.Results: In the absence of added TF, thrombin generation was increased at the surface of SMCs from AAA compared to TAA and HA, indicating a cellular procoagulant phenotype, which is transmitted through mitosis. Phosphatidylserine exposure was increased at the surface of SMCs from AAA. As expected, reactive oxygen species generation and the proinflammatory cytokine TNF-α were increased in SMCs from AAA. Overexpression of protease-activated receptor 2 and nuclear translocation of NF-κB p65 in SMCs and tissue from AAA triggered increased TF gene expression. Higher active basal TF expression was also observed in SMCs from AAA, which was inhibited by BAY 11-7082 (pharmacological inhibitor of IκK) and GB83 (pharmacological inhibitor of PAR-2).Conclusions: We demonstrated a PAR-2-mediated activation of the canonical NF-κB pathway, which triggers TF transcription in AAA. This procoagulant profile is transmitted from tissue to primary SMC cultures and through numerous passages, which can maintain thrombus formation.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatic Apolipoprotein M suppresses hepatocyte secretion of prothrombin by upregulating Arid5B. 肝载脂蛋白M通过上调Arid5B抑制肝细胞凝血酶原的分泌。

IF 4.3 2区医学

Thrombosis and haemostasis Pub Date : 2025-07-24 DOI: 10.1055/a-2664-8170

Makoto Kurano, Baasanjav Uranbileg, Yutaka Yatomi

{"title":"Hepatic Apolipoprotein M suppresses hepatocyte secretion of prothrombin by upregulating Arid5B.","authors":"Makoto Kurano, Baasanjav Uranbileg, Yutaka Yatomi","doi":"10.1055/a-2664-8170","DOIUrl":"https://doi.org/10.1055/a-2664-8170","url":null,"abstract":"Apolipoprotein M (ApoM) is a minor apolipoprotein bound to HDL, which carries sphingosine 1-phosphate (S1P), a potent lipid mediator. Since HDL has been proposed to possess pleiotropic effects, including an anti-thrombotic effect, we investigated the association between ApoM and coagulopathy. ApoM overexpression suppressed and ApoM knockout accelerated the decrease in platelet counts, but ApoM overexpression accelerated and ApoM knockout suppressed the prolongation of prothrombin time and activated partial thromboplastin time in a murine lipopolysaccharide-induced model of sepsis. ApoM decreased the plasma/culture-medium prothrombin levels and increased the hepatic/cellular prothrombin levels in mice and HepG2 cells, a hepatocyte cell line. S1P receptor knockdown did not inhibit prothrombin secretion by HepG2 cells. An RNA-sequence-based approach suggested that Arid5B was involved in these effects of ApoM. Arid5B knockdown increased the culture-medium prothrombin level but decreased cellular prothrombin level. ApoM upregulated Arid5B, and Arid5B knockdown antagonized the inhibitory effect of ApoM on prothrombin secretion. Hepatic ApoM suppresses hepatocyte prothrombin secretion independent of S1P receptors, by upregulation of Arid5B.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to Manage Venous Thromboembolism Risk during Pregnancy in Patients with Inherited Antithrombin Deficiency? 如何管理妊娠期遗传性抗凝血酶缺乏患者静脉血栓栓塞的风险？

IF 5 2区医学

Thrombosis and haemostasis Pub Date : 2025-07-24 DOI: 10.1055/a-2650-7959

Laetitia Mauge, Hugo Madar, Julie Carré, Mathieu Fiore, Nicolas Gendron, Christine Mouton, Valérie Proulle, Pierre Suchon, Nathalie Trillot, Thomas Lechat, Loïc Sentilhes, Laurent Macchi

{"title":"How to Manage Venous Thromboembolism Risk during Pregnancy in Patients with Inherited Antithrombin Deficiency?","authors":"Laetitia Mauge, Hugo Madar, Julie Carré, Mathieu Fiore, Nicolas Gendron, Christine Mouton, Valérie Proulle, Pierre Suchon, Nathalie Trillot, Thomas Lechat, Loïc Sentilhes, Laurent Macchi","doi":"10.1055/a-2650-7959","DOIUrl":"10.1055/a-2650-7959","url":null,"abstract":"Inherited antithrombin deficiency (ATD) is associated with a high risk of venous thromboembolic complications. Association of ATD with other conditions such as pregnancy obviously increases thromboembolic risk and may require anticoagulant therapy for prevention. Although there are several/heterogenous international guidelines regarding thromboprophylaxis in pregnant patients with ATD, data on anticoagulant prophylaxis in this context are scarce in the literature. Thus, this situation remains a challenge both in the antepartum period and during delivery. Physicians from the French Society of Thrombosis and Haemostasis (SFTH) performed a review of the literature to suggest propositions regarding the management of thrombosis prevention based on anticoagulation and antithrombin substitution in ATD pregnant women. In this review, after reporting the thrombotic risk associated with ATD, the indication of anticoagulant therapy, its dosing regimen and monitoring, and the indication of antithrombin concentrates during pregnancy and the postpartum period are discussed as well as peripartum management. Finally, this work confirms the complex management of thrombotic prevention in pregnant patients with ATD. Indeed, it requires to take into account a multiplicity of features cited in our propositions that will hopefully provide some help in this field. This work also highlights the importance of multidisciplinary discussions for pregnant women with ATD who should be counseled in an expert center including hematologist, obstetrician, and anesthetist to optimize their management.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144592431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Critical Review of International Clinical Practice Guidelines Recommendations for Prevention, Diagnosis, and Management of Central Venous Catheter Thrombosis. 中心静脉导管相关血栓形成预防、诊断和处理临床实践指南综述。

IF 5 2区医学

Thrombosis and haemostasis Pub Date : 2025-07-24 DOI: 10.1055/a-2649-9451

Marco Rosson, Mario D'Oria, Chiara Simion, Paolo Simioni, Elena Campello

{"title":"Critical Review of International Clinical Practice Guidelines Recommendations for Prevention, Diagnosis, and Management of Central Venous Catheter Thrombosis.","authors":"Marco Rosson, Mario D'Oria, Chiara Simion, Paolo Simioni, Elena Campello","doi":"10.1055/a-2649-9451","DOIUrl":"10.1055/a-2649-9451","url":null,"abstract":"Central venous catheters (CVCs) are widely used in clinical practice for the administration of medications, parenteral nutrition, and hemodynamic monitoring. However, their use is associated with a significant risk of thrombosis, which can lead to serious complications, including catheter dysfunction, infection, and embolism. Numerous international clinical practice guidelines (CPGs) have been developed to address the prevention, diagnosis, and management of CVC-related thrombosis. This critical review aims to evaluate and compare the recommendations provided by these guidelines, highlighting areas of consensus, variation, and potential gaps. We systematically analyzed CPGs from major healthcare organizations, focusing on key aspects such as risk stratification, prophylactic strategies, diagnostic algorithms, and therapeutic interventions. Although most guidelines emphasize the importance of risk assessment and early intervention, there are notable discrepancies in recommendations regarding the use of anticoagulant prophylaxis, imaging modalities for diagnosis, and the duration of anticoagulation therapy. Additionally, the review explores the evidence underpinning these recommendations and identifies areas where robust clinical data are lacking. Our analysis underscores the need for harmonization across guidelines to ensure consistent and evidence-based care. Furthermore, we advocate for the development of multidisciplinary approaches to enhance decision-making and optimize clinical outcomes in this domain. By addressing the gaps and inconsistencies in current CPGs, this review seeks to provide a framework for improving the prevention, diagnosis, and management of CVC-related thrombosis, ultimately enhancing patient outcomes and reducing the healthcare burden.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TEMPORARY REMOVAL: Validity Considerations for Observational Comparative Effectiveness Studies and Randomized Clinical Trials. 临时切除：观察性比较疗效研究和随机临床试验的有效性考虑。

IF 4.3 2区医学

Thrombosis and haemostasis Pub Date : 2025-07-24 DOI: 10.1055/a-2664-7887

Behnood Bikdeli, Joseph S Ross, Syed Bukhari, Molly M Jeffery, Gregory Yh Lip, Seng Chan You, David J Cohen, James Januzzi, Joshua D Wallach

引用次数: 0

Integrin β3E726 regulates the switch between platelet spreading and clot retraction by interfering Gα13/RhoA pathway. 整合素3e726通过干扰g - α13/RhoA通路调控血小板扩散和凝块收缩之间的转换。

IF 4.3 2区医学

Thrombosis and haemostasis Pub Date : 2025-07-24 DOI: 10.1055/a-2664-7955

Jie Peng, Yichen Liu, Yilin Zhu, Honglei Xin, Yun Wang, Bin Xiao, Tiantian Li, Rong Huang, Jinan Liu, Ruonan Shao, Zijian Li, Jiao Wu, Han Yan, Yongqiu Di, Zijie Gan, Yifei Ma, Jianhua Mao, Shuai Chen, Jiansong Huang, Chao Fang, Xiaodong Xi, Xiaofeng Shi

{"title":"Integrin β3E726 regulates the switch between platelet spreading and clot retraction by interfering Gα13/RhoA pathway.","authors":"Jie Peng, Yichen Liu, Yilin Zhu, Honglei Xin, Yun Wang, Bin Xiao, Tiantian Li, Rong Huang, Jinan Liu, Ruonan Shao, Zijian Li, Jiao Wu, Han Yan, Yongqiu Di, Zijie Gan, Yifei Ma, Jianhua Mao, Shuai Chen, Jiansong Huang, Chao Fang, Xiaodong Xi, Xiaofeng Shi","doi":"10.1055/a-2664-7955","DOIUrl":"https://doi.org/10.1055/a-2664-7955","url":null,"abstract":"Platelet spreading and clot retraction, albeit both mediated by integrin outside-in signaling, lead to platelet shape changes in two opposite directions. The mechanisms by which these processes are regulated are not fully understood. Our previous study found that E726Q mutation in β3 integrin caused impaired spreading in Chinese hamster ovary (CHO) cells on immobilized fibrinogen. The current study further utilized knock-in mice bearing the β3E726Q mutation to explore the underlying mechanisms whereby the E726 residue differentially influences platelet spreading and clot retraction. Compared to wild type (WT) platelets, β3E726Q platelets displayed similar level of β3 expression but partially impaired fibrinogen binding associated with attenuated responses in platelet aggregation and P-selectin exposure. Notably, β3E726Q mutation resulted in defective platelet spreading but accelerated clot retraction concomitant with increased clot density. Functionally, β3E726Q mice displayed prolonged bleeding time and defective thrombogenesis in vitro and in vivo. Further mechanistic study showed that in β3E726Q platelets the activities of RhoA and Rac1 were significantly enhanced following thrombin stimulation, possibly due to reduced binding of Gα13 to the β3 cytoplasmic tail. Taken together, the β3E726 is a potential novel regulatory site that influences the direct interaction of β3 cytoplasmic tail with Gα13 and therefore the activity of downstream RhoA, a molecular switch that shifts platelet spreading into clot retraction.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk factors and outcomes of subsegmental versus more central pulmonary embolism in patients with lung cancer. 肺癌患者亚节段性肺栓塞与中枢性肺栓塞的危险因素和预后。

IF 5 2区医学

Thrombosis and haemostasis Pub Date : 2025-07-21 DOI: 10.1055/a-2661-2326

Delun Yang, Jiajun Deng, Shenghao Huang, Hua He, Chenyang Dai, Deping Zhao, Chang Chen

{"title":"Risk factors and outcomes of subsegmental versus more central pulmonary embolism in patients with lung cancer.","authors":"Delun Yang, Jiajun Deng, Shenghao Huang, Hua He, Chenyang Dai, Deping Zhao, Chang Chen","doi":"10.1055/a-2661-2326","DOIUrl":"https://doi.org/10.1055/a-2661-2326","url":null,"abstract":"Background: The clinical significance of lung cancer-associated subsegmental pulmonary embolism (PE) remains unclear.Methods: This study retrospectively included 902 patients with lung cancer-associated PE (160 subsegmental PE, 742 more central PE). Cox proportional-hazards regression was used to assess the risk of all-cause death. Fine-Gray tests and competing risk models were applied to evaluate the risks (hazard ratio [HR] [95% confidence interval]) of venous thromboembolism (VTE) recurrence and major bleeding. All-cause death was treated as a competing event for both VTE recurrence and major bleeding.Results: Compared with the more central PE group, the subsegmental PE group showed no significant differences in the adjusted risks of VTE recurrence (HR 0.99 [0.62-1.57], p = 0.95) and all-cause death (HR 0.83 [0.52-1.34], p = 0.45), and this finding was consistent across subgroups. Compared with patients with subsegmental PE without anticoagulation, those with anticoagulation had a lower adjusted risk of VTE recurrence (HR 0.16 [0.05-0.53], p = 0.003). The adjusted risks of major bleeding (HR 0.30 [0.05-1.70], p = 0.18) and all-cause death (HR 0.43 [0.13-1.42], p = 0.17) did not reach statistical significance. Independent predictors of VTE recurrence included symptomatic deep vein thrombosis (HR 2.71 [1.63-4.52], p < 0.001), tumor-node-metastasis stage (HR 2.07 [1.19-3.60], p = 0.010), EGFR mutations (HR 0.62 [0.39-0.98], p = 0.041), and anticoagulation (HR 0.32 [0.20-0.52], p < 0.001).Conclusion: The risk of recurrent VTE is not miniscule in patients with lung cancer-associated subsegmental PE.","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0